| Literature DB >> 31887995 |
Aye Mon Phyo1, Ajay M V Kumar2,3,4, Kyaw Thu Soe5, Khine Wut Yee Kyaw2,6, Aung Si Thu1, Pyae Phyo Wai1, Sandar Aye1, Saw Saw7, Htet Myet Win Maung8, Si Thu Aung8.
Abstract
There is no published evidence on contact investigation among multidrug-resistant tuberculosis (MDR-TB) patients from Myanmar. We describe the cascade of contact investigation conducted in 27 townships of Myanmar from January 2018 to June 2019 and its implementation challenges. This was a mixed-methods study involving quantitative (cohort analysis of programme data) and qualitative components (thematic analysis of interviews of 8 contacts and 13 health care providers). There were 556 MDR-TB patients and 1908 contacts, of whom 1134 (59%) reached the health centres for screening (chest radiography and symptoms). Of the latter, 344 (30%) had presumptive TB and of them, 186 (54%) were investigated (sputum microscopy or Xpert MTB/RIF®). A total of 27 TB patients were diagnosed (six bacteriologically-confirmed including five with rifampicin resistance). The key reasons for not reaching township TB centres included lack of knowledge and lack of risk perception owing to wrong beliefs among contacts, financial constraints related to loss of wages and transportation charges, and inconvenient clinic hours. The reasons for not being investigated included inability to produce sputum, health care providers being unaware of or not agreeing to the investigation protocol, fixed clinic days and times, and charges for investigation. The National Tuberculosis Programme needs to note these findings and take necessary action.Entities:
Keywords: MDR-TB; contact investigation; contact tracing; contacts
Year: 2019 PMID: 31887995 PMCID: PMC7157597 DOI: 10.3390/tropicalmed5010003
Source DB: PubMed Journal: Trop Med Infect Dis ISSN: 2414-6366
Figure 1Systematic screening and investigation algorithm for household contacts of index MDR-TB patients in the community-based MDR-TB care project in Myanmar, 2018–19. MDR-TB = multidrug resistant tuberculosis; TB = tuberculosis; CXR = chest X-ray; GXP = Xpert MTB/RIF®; TB symptoms = cough, fever, loss of weight, night sweat, and lymph node enlargement.
Figure 2TB investigation, diagnosis, and treatment of household contacts of MDR-TB patients registered in a community based MDR-TB care project in Myanmar, between January 2018 and June 2019. TB = tuberculosis; MDR-TB = multidrug resistant tuberculosis; CXR = chest X-ray. The numbers in the shaded boxes indicate people with presumptive TB defined as those with symptoms (cough, fever, weight loss, and night sweats) and/or abnormal shadows on the chest radiograph.
Characteristics of TB patients diagnosed among household contacts of MDR-TB patients registered in a community based MDR-TB care project in Myanmar, between January 2018 and June 2019.
| Characteristics | TB Patients | |
|---|---|---|
| N | (%) | |
| Total | 27 | (100) |
|
| ||
| ≤14 | 10 | (37.0) |
| 15–44 | 12 | (44.4) |
| 45–64 | 4 | (14.8) |
| ≥65 | 1 | (3.70) |
|
| ||
| Male | 12 | (44.4) |
| Female | 15 | (55.6) |
|
| ||
| Not tested | 7 | (25.9) |
| No | 15 | (55.6) |
| Yes | 5 | (18.5) |
|
| ||
| Bacteriologically-confirmed | 6 | (22.2) |
| Clinically diagnosed | 21 | (77.8) |
|
| ||
| Pulmonary TB | 26 | (96.3) |
| Extrapulmonary TB | 1 | (3.7) |
TB = tuberculosis; MDR-TB = multidrug resistant tuberculosis.
Factors associated with not being investigated for TB among household contacts with presumptive TB registered in a community-based MDR-TB care project in Myanmar, between January 2018 and June 2019.
| Characteristics | Total | Not Investigated | RR | (95%CI) | aRR | (95%CI) | |
|---|---|---|---|---|---|---|---|
| N | N | (%) | |||||
| Total | 344 | 158 | (45.9) | ||||
|
| |||||||
| ≤14 | 93 | 62 | (66.7) | 1.77 | (1.37–2.28) * | 1.47 | (1.15–1.89) * |
| 15–44 | 143 | 54 | (37.8) | Ref | Ref | ||
| 45–64 | 82 | 34 | (41.5) | 1.10 | (0.79–1.53) | 1.13 | (0.83–1.53) |
| ≥65 | 26 | 8 | (30.8) | 0.81 | (0.44–1.51) | 0.90 | (0.52–1.58) |
|
| |||||||
| Male | 145 | 64 | (44.1) | Ref | Ref | ||
| Female | 199 | 94 | (47.2) | 1.07 | (0.85–1.35) | 1.14 | (0.92–1.42) |
|
| |||||||
| Yes | 185 | 71 | (38.4) | Ref | Ref | ||
| No | 159 | 87 | (54.7) | 1.43 | (1.13–1.80) * | 1.08 | (0.87–1.34) |
|
| |||||||
| Yes | 27 | 17 | (63) | 1.42 | (1.03–1.94) * | NE | |
| No | 317 | 141 | (44.5) | Ref | |||
|
| |||||||
| Yes | 65 | 35 | (53.8) | 1.22 | (0.94–1.59) | NE | |
| No | 279 | 123 | (44.1) | Ref | |||
|
| |||||||
| Without GXP | 40 | 28 | (70) | 1.64 | (1.29–2.08) * | 1.60 | (1.24–2.07) * |
| With GXP | 304 | 130 | (42.8) | Ref | Ref | ||
|
| |||||||
| Patient | 299 | 157 | (52.5) | 23.63 | (3.39–164.6) * | 20.46 | (2.88–145.53) * |
| Sputum Sample | 45 | 1 | (2.2) | Ref | Ref | ||
|
| |||||||
| Mandalay | 196 | 83 | (42.3) | Ref | Ref | ||
| Sagaing | 76 | 37 | (48.7) | 1.15 | (0.87–1.53) | 1.20 | (0.89–1.62) |
| Shan | 38 | 19 | (50) | 1.18 | (0.83–1.69) | 1.18 | (0.85–1.65) |
| Magway | 34 | 19 | (55.9) | 1.32 | (0.94–1.85) | 1.06 | (0.74–1.51) |
TB = tuberculosis; MDR-TB = multidrug resistant tuberculosis; GXP = Xpert MTB/RIF® machine; CI = confidence interval; RR = relative risk; aRR = adjusted relative risk; n = number; NE = not estimated.* = statistically significant. The variables that were significant in the unadjusted analysis and that were found to be associated in previous studies were included in the adjusted analysis. Fever was not included in the adjusted model owing to collinearity with cough.
Factors associated with GXP testing among household contacts with presumptive TB registered in a community-based MDR-TB care project in Myanmar, between January 2018 and June 2019.
| Characteristics | Total | GXP Tested | RR | (95%CI) | aRR | (95%CI) | |
|---|---|---|---|---|---|---|---|
| N | N | (%) | |||||
| Total | 344 | 121 | (35.2) | ||||
|
| |||||||
| ≤14 | 93 | 22 | (23.7) | 0.53 | (0.35–0.79) * | 0.54 | (0.35–0.82) * |
| 15–44 | 143 | 64 | (44.8) | Ref | Ref | ||
| 45–64 | 82 | 28 | (34.1) | 0.76 | (0.54–1.08) | 0.75 | (0.53–1.05) |
| ≥65 | 26 | 7 | (26.9) | 0.60 | (0.31–1.16) | 0.59 | (0.31–1.12) |
|
| |||||||
| Male | 145 | 53 | (36.6) | Ref | Ref | ||
| Female | 199 | 68 | (34.2) | 0.93 | (0.70–1.25) | 0.95 | (0.72–1.25) |
|
| |||||||
| Yes | 185 | 75 | (40.5) | 1.40 | (1.04–1.89) * | 1.06 | (0.78–1.45) |
| No | 159 | 46 | (28.9) | Ref | Ref | ||
|
| |||||||
| Without GXP | 40 | 7 | (17.5) | Ref | Ref | ||
| With GXP | 304 | 114 | (37.5) | 2.14 | (1.08–4.27) * | 2.14 | (1.1–4.17) |
|
| |||||||
| Patient | 299 | 101 | (33.8) | Ref | Ref | ||
| Sputum Sample | 45 | 20 | (44.4) | 1.32 | (0.92–1.89) | 1.16 | (0.8–1.69) |
|
| |||||||
| Mandalay | 196 | 76 | (38.8) | Ref | Ref | ||
| Sagaing | 76 | 21 | (27.6) | 0.71 | (0.48–1.07) | 0.67 | (0.44–1.03) |
| Shan | 38 | 18 | (47.4) | 1.22 | (0.84–1.78) | 1.21 | (0.85–1.73) |
| Magway | 34 | 6 | (17.6) | 0.46 | (0.22–0.96) * | 0.51 | (0.24–1.08) |
|
| |||||||
| No Symptom | 103 | 31 | (30.1) | Ref | NE | ||
| Any Symptom | 241 | 90 | (37.3) | 1.24 | (0.89–1.74) | ||
TB = tuberculosis; MDR-TB = multidrug resistant tuberculosis; GXP = Xpert MTB/RIF® machine; CI = confidence interval; RR = relative risk; aRR = adjusted relative risk, n = number; NE = not estimated. * = statistically significant. The variables that were significant in the unadjusted analysis and that were found to be associated in previous studies were included in the adjusted analysis.
Median duration (days) between different steps in the cascade of contact investigation among household contacts registered in community-based MDR-TB care project in Myanmar, between January 2018 and June 2019.
| Duration (Days) | Total Eligible | Number (%) with Valid Dates | Median Days | (IQR) |
|---|---|---|---|---|
| Treatment start of index MDR-TB case and contact screening | 1134 | 1005 (89) | 81 | (28–208) |
| Contact screening and investigation | 399 | 380 (95) | 0 | (0–1) |
| TB diagnosis and treatment initiation | 26 | 26 (100) | 8 | (2–14) |
| Bacteriologically-confirmed TB | 5 | 5 (100) | 14 | (14–15) |
| Clinically diagnosed TB | 21 | 21 (100) | 4 | (2–10) |
TB = tuberculosis; MDR-TB = multidrug resistant tuberculosis; IQR = inter quartile range.